1. Home
  2. BST vs PGEN Comparison

BST vs PGEN Comparison

Compare BST & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Science and Technology Trust of Beneficial Interest

BST

BlackRock Science and Technology Trust of Beneficial Interest

HOLD

Current Price

$35.34

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$3.66

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BST
PGEN
Founded
2014
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
BST
PGEN
Price
$35.34
$3.66
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$8.33
AVG Volume (30 Days)
68.2K
4.2M
Earning Date
01-01-0001
03-25-2026
Dividend Yield
11.60%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$230,981,000.00
Revenue This Year
N/A
$938.10
Revenue Next Year
N/A
$108.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.87
$1.11
52 Week High
$44.50
$5.47

Technical Indicators

Market Signals
Indicator
BST
PGEN
Relative Strength Index (RSI) 24.14 50.74
Support Level N/A $3.49
Resistance Level $41.42 $5.10
Average True Range (ATR) 0.79 0.22
MACD -0.30 0.07
Stochastic Oscillator 2.30 50.61

Price Performance

Historical Comparison
BST
PGEN

About BST BlackRock Science and Technology Trust of Beneficial Interest

BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objective is to provide income and total return through a combination of current income, current gains, and long-term capital appreciation. It focuses on investing, under a normal market condition in equity securities of science and technology companies.

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Share on Social Networks: